JPY 6,864.00
-69.00 (-1.00%)
JPY · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 4519.T is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
54 interventional · 9 observational · 1 with posted results
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerNCT07617337Adverse events [PartA,B]Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: AQUA07, Lorlatinib | ALK Positive Non-small Cell Lung Cancer | 102 | 2030-08-31 | in 1,473 d | 2026-08-19 |
| Study of AUBE00 in Patients With Solid TumorsNCT07030959Adverse events of AUBE00 [Part A, B, C]Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: AUBE00, Cetuximab | Solid Tumors | 130 | 2029-12-31 | in 1,230 d | 2026-07-20 |
| A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCERNCT07107490All part : Adverse events of ALPS12[safety and tolerability]Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ALPS12, obinutuzumab | Extensive Stage Small Cell Lung Cancer | 122 | 2028-09-30 | in 773 d | 2026-02-06 |
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)NCT06723106Adverse events (AEs)Open-label · Treatment | Phase 1 | Enrolling by invitation | Drug: RAY121 | Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP) | 144 | 2028-02-28 | in 558 d | 2026-07-17 |
| A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid TumorsNCT05907980The maximum tolerated dose (MTD) and the recommended dose (RD) of ROSE12 when administered as a single agent and in combination with atezolizumab (Part A and C)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ROSE12, Atezolizumab, Pembrolizumab | Solid Tumor | 209 | 2027-10-31 | in 438 d | 2026-07-28 |
| Study of DONQ52 in Active Celiac DiseaseNCT07239336Change in Villous Height to Crypt Depth Ratio (Vh:Cd)Randomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: Placebo DONQ52, DONQ52 · Dietary supplement: Simulated Inadvertent Gluten Exposure (SIGE) capsule, Simulated Inadvertent Gluten Exposure (SIGE) capsule | Celiac Disease | 92 | 2027-06-15 | in 300 d | 2026-08-14 |
| Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)NCT06371417Adverse events (AEs)Open-label · Treatment | Phase 1 | Recruiting | Drug: RAY121 | Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP) | 144 | 2027-03-31 | in 224 d | 2026-07-22 |
| A Phase I Study of ERY974 in Patients With Hepatocellular CarcinomaNCT05022927Safety and tolerability of ERY974 in combination with atezolizumab and bevacizumab (Dose limiting toxicities) [Dose escalation part]Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: ERY974, Tocilicumab, Atezolizumab, Bevacizumab | Hepatocellular Carcinoma (HCC) | 179 | 2025-12-31 | — | 2024-09-05 |
| A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).NCT04511845Safety and tolerability of SPYK04 (Dose limiting toxicities) [Dose escalation]Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: SPYK04 | Locally Advanced or Metastatic Solid Tumors | 85 | 2026-06-18actual | — | 2026-07-30 |
| A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid TumorsNCT05735366Adverse events of SAIL66[safety and tolerability]Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: SAIL66 | Solid Tumor | 22 | 2026-01-26actual | — | 2026-03-10 |
| A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).NCT05012618Safety and tolerability of LUNA18 (Dose-limiting toxicities) when administered as a single agent [Part A] and in combination with other anti-cancer drugs [Part D]Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decided to discontinue this study upon having LPLV. | Drug: LUNA18, Cetuximab | Locally Advanced or Metastatic Solid Tumors | 128 | 2025-11-13actual | — | 2025-12-24 |
| Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal OsteoporosisNCT05433207observationalthe rates of hypercalcemia and 95% confidence intervals for patients with and without calcium preparation intake | — | Unknown status | Drug: Eldecalcitol soft capsules | Postmenopausal Osteoporosis | 1,000 | 2025-01-31 | — | 2022-06-27 |
| Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease PatientsNCT05425446Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or higherRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: DONQ52, Placebo | Celiac Disease | 56 | 2024-08-09actual | — | 2025-01-31 |
| A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)NCT05686369observationalThe concordance between the novel digital biomarker and the presence of celiac disease-related symptoms | — | Completed | — | Celiac Disease | 12 | 2023-10-05actual | — | 2023-11-03 |
| Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)NCT04501497observational12 months survival rate | — | Completed | — | Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer | 1,221 | 2023-02-03actual | — | 2024-04-02 |
| The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)NCT04818983observationalCorrelation between PD-L1 SNP and atezolizumab combination therapy | — | Completed | — | Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer | 470 | 2023-02-03actual | — | 2024-04-02 |
| An Observational Study of Patients With Endometriosis to Evaluate the Usefulness of the MEDL Score, a New Method for Evaluating Endometriosis Using MRINCT04846582observationalCorrelation of MEDL score assessed by MRI and laparoscopy | — | Completed | — | Endometriosis | 73 | 2023-01-10actual | — | 2023-09-22 |
| CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRCNCT04097444Progression-free survival (PFS)Randomized · Open-label · Treatment | Phase 2 | Unknown status | Biological: Bevacizumab · Drug: 5-fluorouracil, Leucovorin calcium, Irinotecan hydrochloride, Oxaliplatin, Capecitabine | Metastatic Colorectal Cancer | 112 | 2022-08-31 | — | 2019-10-31 |
| A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy VolunteerNCT04708847Thigh muscle strength scoreRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: GYM329, Placebo | Healthy Volunteers | 30 | 2022-06-03actual | — | 2023-02-17 |
| PD-L1 Expression in Japanese Renal Cell Carcinoma PatientsNCT03748901observationalOverall survival in PD-L1 negative (IC0) and positive (IC1/2/3) patients. | — | Completed | — | Renal Cell Carcinoma | 830 | 2021-07-21actual | — | 2021-08-30 |
| A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)NCT03645330observational18 months survival rate | — | Completed | — | Non-small-Cell Lung Cancer | 1,026 | 2021-07-08actual | — | 2022-07-22 |
| Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371NCT04649216Mass balance data for [14C]PCO371 Oral solution in urineNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: PCO371, [14C]PCO371, [14C]PCO371 | Healthy Volunteers | 11 | 2020-12-30actual | — | 2021-03-01 |
| A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With HypoparathyroidismNCT04209179Treatment-emergent adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Terminated on the basis of the currently uncertain risk-benefit balance for the patients, and the strategic position of the development program | Drug: PCO371, Placebo | Hypoparathyroidism | 5 | 2020-12-28actual | — | 2021-06-11 |
| A Study of ERY974 in Patient With Advanced Solid TumorsNCT02748837Dose escalation： MTD determinationNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ERY974 | Solid Tumors | 29 | Aug 2019actual | — | 2019-08-22 |
| A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on HemodialysisNCT02965053Safety: Incidences of adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: EOS789, Placebo, Renvela | Hyperphosphatemia | 26 | Aug 2018actual | — | 2018-09-13 |
| Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30NCT02431117observationalSuitability for individuals with Down syndrome assessed by number of tests completed and number of participants completing the tests, variance estimate of baseline and of the change from baseline values. | — | Completed | — | Down Syndrome | 43 | Jul 2016actual | — | 2016-07-11 |
| A Single Ascending Dose Study of PCO371 in Healthy VolunteersNCT02475616Safety as assessed by adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Terminated | Drug: PCO371, Placebo | Healthy | 64 | Oct 2015actual | — | 2015-11-20 |
| A Phase 2 Study of CIM331 for Atopic Dermatitis PatientsNCT01986933results2021-11-22Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: nemolizumab (CIM331) · Other: Placebo | Atopic Dermatitis | 264 | Apr 2015actual | — | 2022-01-25 |
| A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease PatientsNCT01656525Number of participants with Adverse EventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Gantenerumab, Gantenerumab, Gantenerumab, Placebo | Alzheimer's Disease | 28 | Mar 2014actual | — | 2014-09-19 |
| Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)NCT00976170Toxicity evaluation in accordance with CTCAE v3.0Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: GC33(RO5137382), Sorafenib | Hepatocellular Carcinoma | 42 | Jul 2013actual | — | 2014-10-03 |
| Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary OsteoporosisNCT00447915Incidence of vertebral fractureRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: ibandronic acid 0.5mg, RIS placebo, 1.0mg ibandronic acid, ibandronic acid placebo, 2.5mg RIS · Dietary supplement: Calcium and Vitamine D3 | Primary Osteoporosis | 1,265 | Aug 2011actual | — | 2012-08-02 |
| A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)NCT00746317Determine the safety and tolerability of escalating doses of GC33Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: GC33 | Advanced or Metastatic HCC | 27 | Oct 2010actual | — | 2012-10-17 |
| Trial of Pegasys® in Patients With Chronic Hepatitis CNCT00245414Sustained viral response as undetectable level of HCV-RNANon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Pegasys®, Pegasys® | Chronic Hepatitis C | 108 | Jul 2010actual | — | 2010-11-17 |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid ArthritisNCT00779220Percentage of patients with ACR20 response.Randomized · Quadruple-masked · Treatment | Phase 2 | Terminated | Drug: placebo, methotrexate, ocrelizumabu 50mg, ocrelizumabu 200mg, ocrelizumab 500mg | Rheumatoid Arthritis | 152 | Feb 2010actual | — | 2015-03-25 |
| A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)NCT00304551Sustained virological response, defined as undetectable hepatitis C virus (HCV)-RNA (< 50 IU per milliliter [IU/mL])Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: peginterferon alfa-2a 180μg, peginterferon alfa-2a 90μg, ribavirin | Liver Cirrhosis, Chronic Hepatitis C | 180 | Dec 2009actual | — | 2010-06-03 |
| Study of MRA in Patients With Rheumatoid Arthritis (RA)NCT00144651ACR 20% responder rate compared to the pre-treatment in the preceding studyNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: MRA(Tocilizumab) | Rheumatoid Arthritis | 135 | Jun 2009actual | — | 2013-08-09 |
| Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast CancerNCT00467012SafetyNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: bevacizumab, Paclitaxel | Metastatic Breast Cancer | 122 | Jun 2009actual | — | 2012-04-26 |
| Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) PatientsNCT00628043The proportion of the subjects who receive red blood cell (RBC) transfusion and/or hemoglobin (Hb) concentration < 8.0 g/dLRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: epoetin beta, placebo | Anemia | 160 | May 2009actual | — | 2009-09-18 |
| A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)NCT00661284observationalProportion of patients who maintained efficacy during 52-weeks after the last infusion of MRA in the previous studies. | — | Completed | — | Rheumatoid Arthritis | 189 | Mar 2009actual | — | 2012-08-02 |
| Clinical Study of R744 to Predialysis PatientsNCT00433615Ratio of Maintenance of target Hb concentrationNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: R744, R744 | Anemia in Pre-Dialysis Patients | 124 | Nov 2008actual | — | 2009-02-02 |
| Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal CancerNCT00345761Response rate: Response Evaluation Criteria in Solid Tumors (RECIST)Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Bevacizumab, Oxaliplatin, Capecitabine | Colorectal Cancer | 64 | Oct 2008actual | — | 2010-08-16 |
| Clinical Study of R744 to Peritoneal Dialysis PatientsNCT00433849Rate of patients who maintain Hb concentration in the range of ≥ 10.0g/dL and ≤ 12.0g/dLNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: R744, R744 | Peritoneal Dialysis Patients | 72 | Oct 2008actual | — | 2009-02-02 |
| A New Active Vitamin D, ED-71 for OsteoporosisNCT00144456Incidences of vertebral fractureRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: ED-71, Alfacalcidol, ED-71 placebo, Alfacalcidol placebo | Osteoporosis | 1,056 | Sep 2008actual | — | 2013-08-09 |
| Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JPNCT00144547Patients fron MRA Group of previous study:The frequency of amelioration of at least 20% in terms of the ACR criteria compared to the beginning of the treatment in previous study(MRA012JP)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MRA(Tocilizumab) | Rheumatoid Arthritis | 241 | Aug 2008actual | — | 2013-08-09 |
| Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JPNCT0014458620% improvement based on the American College of Rheumatology (ACR) criteria compared with the baseline value in the previous study.Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MRA(Tocilizumab) | Rheumatoid Arthritis | 42 | Aug 2008actual | — | 2013-08-09 |
| PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)NCT00380601Frequency of ACR 20％ improvement at the final visitNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MRA(Tocilizumab) | Rheumatoid Arthritis | 20 | Aug 2008actual | — | 2009-12-23 |
| Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)NCT00433888Rate of patients who maintain Hb concentration in the range of ≥ 10.0g/dL and ≤ 12.0g/dLNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: R744, R744 | Hemodialysis Patients | 179 | Jul 2008actual | — | 2009-02-02 |
| Clinical Study of R744 to Hemodialysis PatientsNCT00491868Variation of Hb concentration from baseline Hb concentration in evaluation periodRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: R744, R744, rHuEPO, rHuEPO, R744 placebo, rHuEPO placebo | Hemodialysis Patients | 134 | May 2008actual | — | 2009-02-02 |
| Correction Study of R744 in Renal Anemia Patients on HemodialysisNCT00433693The ratio of patients whose Hb concentration reach ≥ 10.0g/dL and increasing amount of Hb concentration reach ≥ 1.0g/dLNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: R744 | Hemodialysis Patients | 50 | Mar 2008actual | — | 2009-02-02 |
| Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)NCT00492427Rate of patients who maintain mean Hb concentration in the range of ≥ 10.0g/dL and ≤ 12.0g/dLRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: R744, Epoetin beta | Predialysis Patients | 187 | Jan 2008actual | — | 2009-01-08 |
| Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal ImpairmentNCT0014457320% improvement based on the ACR criteria compared with the baseline value.Non-randomized · Open-label · Treatment | Not applicable | Completed | Drug: MRA(Tocilizumab) | Rheumatoid Arthritis | 14 | Oct 2005actual | — | 2008-12-15 |
| Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JPNCT00144534Efficacy:the frequency of amelioration of at least 20% in terms of the ACR criteriaNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MRA (Tocilizumab) | Rheumatoid Arthritis | 115 | Aug 2005actual | — | 2009-12-23 |
| Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)NCT0014456020% improvement based on the ACR criteria compared with the baseline value.Randomized · Open-label · Treatment | Not applicable | Completed | Drug: MRA(Tocilizumab) | Rheumatoid Arthritis | 31 | Aug 2005actual | — | 2008-12-15 |
| Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)NCT00144625Efficacy:Percentage of patients showing 30% improvement in the JIA core set every 3M, LOBSNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MRA(Tocilizumab) | Polyarticular Juvenile Idiopathic Arthritis | 19 | Jul 2005actual | — | 2009-12-23 |
| Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)NCT00144612Efficacy:Percentage of patients showing 30% improvement in the JIA core set compared with before the first infusion of the investigational product (including the previous study)Non-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MRA(Tocilizumab) | Systemic Juvenile Idiopathic Arthritis | 60 | Jun 2005actual | — | 2009-12-23 |
| Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)NCT00144664Efficacy:Percentage of patients showing 30% improvement in the JIA core set on LOBSNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MRA(Tocilizumab) | Systemic Juvenile Idiopathic Arthritis | 19 | Apr 2005actual | — | 2008-07-30 |
| A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing ChemotherapyNCT00144482The increase in Hb concentrationRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: recombinant human erythropoietin, recombinant human erythropoietin placebo | Chemotherapy Induced Anemia | 122 | Mar 2005actual | — | 2009-02-02 |
| A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing ChemotherapyNCT00144495The increase in Hb concentrationNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: recombinant human erythropoietin, recombinant human erythropoietin | Chemotherapy Induced Anemia | 104 | Nov 2004actual | — | 2009-02-02 |
| Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone MetastasesNCT00060138Randomized · Double-masked · Supportive care | Phase 1/2 | Completed | Biological: monoclonal antibody CAL · Drug: zoledronic acid | Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain | — | Sep 2004actual | — | 2013-05-15 |
| Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)NCT00144521Frequency of ACR 20% improvementRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: MRA(Tocilizumab), MRA placebo, MTX, MTX placebo | Rheumatoid Arthritis | 127 | Aug 2004actual | — | 2009-02-02 |
| Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)NCT00144508Change in the erosion score, as determined by the modified Sharp method.Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: MRA (Tocilizumab) · Other: current treatment | Rheumatoid Arthritis | 306 | May 2004actual | — | 2009-02-02 |
| A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis CNCT00144469Sustained virological response, defined as undetectable HCV-RNA (<50IU per milliliter) after 24 weeks of untreated follow-up (week 72).Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: peginterferon alfa-2a, rivavirin | Chronic Hepatitis C | 300 | — | — | 2009-02-02 |
| Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)NCT00144599Efficacy:Percentage of patients showing 30% improvement in the JIA core set, Percentage of patients showing improvement in CRP on LOBSRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: MRA(Tocilizumab), placebo | Systemic Juvenile Idiopathic Arthritis | 56 | — | — | 2008-07-30 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19